• Manage company strategies and daily operations• Manage research and development, regulatory filing, and marketing of clinical diagnostics products

• Counseled on patent filing, licensing, acquisition, and portfolio management• Managed the entire process of patent litigation

• Screened brand pharmaceutical products with innovative legal and economic models and build Paragraph IV and ANDA pipeline• Oversaw bioequivalence development and regulatory filings of generic products• Counseled on patent licensing, acquisition and portfolio management• Managed all aspects of patent litigation from pre-filing investigation to trial

• Built innovative financial and legal models and software for generic pharmaceutical companies to automate product screening for Paragraph IV litigation and optimization of ANDA pipelines• Examined the generic company's current product portfolio and conducted gap analysis to identify opportunities to expand its coverage of generic market, particularly on products with stronger barriers to entry• Identified opportunities of growth for the generic companies from current brand products using the (A)NDA portfolio and product life cycle management tools• Developed a settlement model that systematically assesses the asymmetric risks in Paragraph IV-derived patent infringement litigation and allows the generic or the brand to make the most economically efficient and legally sound settlement decisions that can avoid FTC or DOJ scrutiny• Analyzed and advised on strategic growth initiatives including in-licensing, strategic alliance and acquisition options for pharmaceutical clients• Provided advisory and litigation consulting on the retention of market exclusivity for innovative products through all stages of the life cycle• Performed intellectual property valuations to assess clinical pipelines for clients ranging from large pharmaceutical companies to small biotechs• Designed a series of highly quantitative- and legal-based trading strategies and financial instruments for pharmaceutical companies to hedge their R&D risk, catastrophe market loss, global price risk, and loss of exclusivity risk

• Researched expert testimonies, scientific literature and documentation and, as well as court’s admission of expert testimonies to evaluate strength of patent claims• Advised on deposition strategies in a patent litigation

• Developed advanced analytics on longitudinal prescription data and provided market insights to senior business teams to promote sales and persistent use of brand name drugs• Designed and implemented an innovative marketing strategy and associated incentive structures to improve patient persistency through third-party payors

• Identified and evaluated advanced technologies for in-licensing and partnership opportunities on Merck’s global biomarker initiative. Designed and implemented a series of pilot studies that led to Merck’s investment of $140M over 3 years on a JV with a California-based medical device company• Evaluated and managed vendors on outsourcing of clinical development and biomarker discovery• Led all analytics in Merck-Foxhollow cardiovascular biomarker discovery JV in a team of over 200

• Developed statistical methods and software for association and linkage studies and microarray experiments. Commercialized SAS/Genetics with over $1M revenue each year since 2003

Developed statistical software Genetic Analysis Workbench (GAW) for linkage and association gene mapping.